Mert Aktar
CIK: 0002040256
Associated companies
Transaction History
| KYTX | ▲ Buy | Grant | 5,093 | $0 | 5/27/2026 | View on chart |
| KYTX | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 | View on chart |
| KYTX | ▲ Buy | Grant | 5,093 | $0 | 5/27/2026 | View on chart |
| KYTX | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials
Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.